Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059]
Corresponding Author of This Article
Moo In Park, MD, Professor, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, South Korea. email@example.com
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Hae Koo Kim, Young Dal Lee
Sung Eun Kim, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Hae Koo Kim, Young Dal Lee, Department of Internal Medicine, Kosin University College of Medicine, Busan 49267, South Korea
ORCID number: $[AuthorORCIDs]
Author contributions: Kim SE interpreted and analyzed the data and wrote the manuscript; Park MI designed, organized, and supervised writing of the manuscript; Park SJ and Moon W helped with data interpretation that was used in the current study; Kim JH and Jung K provided input and organized the data for statistical analysis; Kim HK and Lee YD helped with data analysis; all authors approved the final version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Kosin University Gospel Hospital Institutional Review Board (IRB file No. 2015-03-018).
Conflict-of-interest statement: We have no conflicts of interest regarding the current paper.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Moo In Park, MD, Professor, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 49267, South Korea. firstname.lastname@example.org
Telephone: +82-51-9906719 Fax: +82-51-9905055
Received: October 17, 2016 Peer-review started: October 18, 2016 First decision: October 28, 2016 Revised: November 21, 2016 Accepted: January 18, 2017 Article in press: January 18, 2017 Published online: February 14, 2017
To investigate Helicobacter pylori (H. pylori) eradication rates using second-line bismuth-containing quadruple therapy and to identify predictors of eradication failure.
This study included 636 patients who failed first-line triple therapy and received 7 d of bismuth-containing quadruple therapy between January 2005 and December 2015. We retrospectively demonstrated H. pylori eradication rates with respect to the year of therapy as well as demographic and clinical factors. H. pylori eradication was confirmed by a 13C-urea breath test or a rapid urease test at least 4 wk after the completion of bismuth-based quadruple therapy: proton pump inhibitor, metronidazole, bismuth, and tetracycline.
The overall eradication rates by intention-to-treat analysis and per-protocol analysis were 73.9% (95%CI: 70.1%-77.4%) and 94.5% (95%CI: 92.4%-96.5%), respectively. Annual eradication rates from 2005 to 2015 were 100.0%, 92.9%, 100.0%, 100.0%, 100.0%, 97.4%, 100.0%, 93.8%, 84.4%, 98.9%, and 92.5%, respectively, by per-protocol analysis. A multivariate analysis showed that diabetes mellitus (OR = 3.99, 95%CI: 1.56-10.20, P = 0.004) was associated with H. pylori eradication therapy failure.
The second-line bismuth-containing quadruple therapy for H. pylori infection is still effective in Korea, and diabetes mellitus is suggested to be a risk factor for eradication failure.
Core tip: This study investigated the efficacy of 7 d of second-line bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) infection and identified risk factors for eradication failure in South Korea. The overall eradication rate per-protocol analysis was 94.5% in the current study. Additionally, diabetes mellitus was related to H. pylori eradication therapy failure. Therefore, second-line bismuth-containing quadruple therapy for H. pylori infection is still worth considering in South Korea, and diabetes mellitus is suggested to be a risk factor for eradication failure.
Citation: Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066
Helicobacter pylori (H. pylori) is a global pathogen that causes gastritis, peptic ulcers, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. The International Agency for Research on Cancer, a branch of the World Health Organization, has declared that H. pylori is a definite gastric carcinogen (group I)[2,3]. Therefore, H. pylori eradication is crucial to maintain public health, especially in high H. pylori and gastric cancer prevalence areas.
Various combination therapies are recommended for H. pylori eradication due to a decrease in eradication rates. According to the Maastricht IV/Florence consensus report, clarithromycin-containing therapy [comprised of a proton pump inhibitor (PPI), amoxicillin, and clarithromycin] is recommended for first-line eradication treatment, and bismuth-containing quadruple therapy (comprised of a PPI, metronidazole, bismuth, and tetracycline) is recommended for second-line eradication treatment if first-line eradication therapy fails. Guidelines for the treatment of H. pylori infection in South Korea are similar to recommendations in the Maastricht IV/Florence consensus report. Specifically, clarithromycin-containing triple therapy is the recommended first-line eradication therapy, and bismuth-containing quadruple therapy is recommended for the second-line eradication treatment if the clarithromycin-based triple therapy fails.
In general, clarithromycin-containing therapy is recommended for first-line eradication treatment in low (< 20%) clarithromycin resistance areas. However, the eradication rates for clarithromycin-containing triple therapy have been decreasing significantly in Korea in recent years due to increased H. pylori antibiotic resistance[6,7]. In addition, there is controversy about the role of bismuth-containing quadruple therapy as a second-line therapy for H. pylori eradication due to a decrease in eradication rates for bismuth-containing quadruple therapy in Korea[8,9].
The aims of the present study were to identify the effects of second-line eradication therapy using bismuth-containing quadruple therapy at a single center over the past 11 years, and to evaluate risk factors associated with the failure of second-line eradication therapy.
MATERIALS AND METHODS
Patients who failed clarithromycin-containing triple therapy and received second-line bismuth-containing quadruple therapy at Kosin University Gospel Hospital from January 2005 to December 2015 were retrospectively enrolled in this study. H. pylori positivity was identified using a 13C-urea breath test or a rapid urease test before and after eradication therapy. Patients lost to follow-up were defined as patients who received the second-line bismuth-containing quadruple therapy with unknown results regarding eradication success or failure. Compliance was classified as good or poor by pill count in the medical records. Patients who took 80% or more of the prescribed medicine were included in the good compliance group, and those who took less than 80% of the prescribed medicine were placed in the poor compliance group.
We investigated demographic features: area of residence, smoking and alcohol habits, diabetes mellitus, hypertension, endoscopic findings, and adverse effects of eradication therapy. Rural or urban residence was regarded as living or not living in the metropolitan cities of Korea, respectively. All patients underwent endoscopy, and endoscopic findings [such as gastric ulcers, duodenal ulcers, gastric and duodenal ulcers, a previous endoscopic submucosal dissection (ESD) state due to adenoma or early gastric cancer (EGC), MALT lymphoma, nodular gastritis, dyspepsia, gastric polyps, and intestinal metaplasia] were identified by endoscopy or by endoscopy with biopsy. Adverse effects after eradication therapy were identified by verification in the medical records. The Institutional Review Board (IRB) of Kosin University Gospel Hospital approved this study (IRB file No. 2015-03-018).
H. pylori eradication therapy and follow-up
Patients who failed the first-line clarithromycin-containing triple therapy (standard-dose PPI, 1.0 g amoxicillin, and 0.5 g clarithromycin twice daily for 7 d) were recommended for second-line eradication therapy. The latter was comprised of 20 mg rabeprazole twice daily, 500 mg metronidazole three times daily, 300 mg tripotassium dicitrato bismuthate, and 500 mg tetracycline four times daily for 7 d. Afterwards, a 13C-urea breath test or a rapid urease test was conducted to assess H. pylori eradication at least 4 wk after the treatment completion, and at least 2 wk after cessation of PPIs or histamine (H2) receptor antagonists.
13C-urea breath test
Patients fasted for at least 4 h before the first breath sample was collected. Then, participants took tablets including 100 mg of 13C-urea (UBiTkit™, Otsuka Pharmaceutical, Tokyo, Japan) with 100 mL of water orally, and the second breath sample was obtained 20 min after taking the tablets. H. pylori infection was analyzed using the 13C-urea breath test (UBiT-IR300®; Otsuka Electronics, Osaka, Japan) on the collected breath samples. The cut-off value in the current procedure was set at 2.5‰.
Rapid urease test
To identify H. pylori infection with the rapid urease test (CLOtest®; Delta West, Bentley, WA, Australia), an endoscopic biopsy was conducted at the gastric mucosa. The site of gastric mucosal biopsy was antrum and/or corpus, and normal or near-normal gastric mucosa with little atrophy or intestinal metaplasia was removed. The tissue sample was immersed in rapid urea reagent. The result was positive when the reagent color changed from yellow to red at least 12 h later, and the result was negative when there was no change in reagent color.
All statistical analyses were conducted with the Statistical Package for the Social Sciences software version 20.0 (SPSS, Chicago, IL, United States). The H. pylori eradication rate was demonstrated by intention-to-treat (ITT) and per-protocol (PP) analyses. The trend in H. pylori eradication rates was analyzed with linear association. Patients lost to follow-up or those with poor compliance were excluded when we performed the PP analysis and univariate and multivariate logistic regression analyses. Categorical variables were analyzed using a χ2-test, and continuous variables were analyzed using the Student's t-test. Univariate and multivariate logistic regression tests were used for the analysis of risk factors, which were expressed as an OR and 95%CI. A P value < 0.05 was considered statistically significant.
Between January 2005 and December 2015, 636 patients received 7 d of second-line bismuth-containing quadruple therapy after H. pylori eradication failure with clarithromycin-based triple therapy. Average age (mean ± SD) was 54.6 ± 11.6 years (range, 17-86 years), and 354 patients (55.7%) were male. Table 1 shows the clinical data and demographic information for enrolled patients. Among 636 patients receiving second-line bismuth-containing quadruple therapy, 138 patients were lost to follow-up, and three patients exhibited poor compliance. Finally, a total of 495 patients were included as subjects for PP analysis and multivariate logistic regression (Figure 1).
Table 1 Baseline characteristics of the patients n (%).
1Total number of enrolled patients; missing values are not included. The number behind the dash is the total number of subjects who answered each question.
2Others include MALT lymphoma, dyspepsia, gastric polyp and intestinal metaplasia. ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; MALT lymphoma: Mucosa-associated lymphoid tissue lymphoma.
Figure 1 Flowchart of the study participants.
ITT: Intention-to-treat; PP: Per-protocol; H. pylori: Helicobacter pylori.
H. pylori eradication rates
In terms of eradication therapy success or failure, 468 patients achieved successful eradication. The eradication rates by ITT and PP analyses were 73.9% (95%CI: 70.1%-77.4%) and 94.5% (95%CI: 92.4%-96.5%) for second-line quadruple therapy, respectively. Annual eradication rates from 2005 to 2015 were 100.0%, 92.9%, 100.0%, 100.0%, 100.0%, 97.4%, 100.0%, 93.8%, 84.4%, 98.9% and 92.5%, consecutively by PP analysis. The eradication rate for first-line triple therapy decreased over the years (P = 0.01). Figure 2 presents the annual eradication rates for the last 11 years.
Figure 2 Helicobacter pylori eradication rates of second-line bismuth-based quadruple therapy according to years (P = 0.01).
Adverse effects of eradication therapy
Of the 495 patients, 74 patients (14.9%) complained of adverse events after bismuth-based quadruple therapy; fortunately, the adverse events were mild or moderate. Adverse events possibly related to treatment were diarrhea in 16 patients (3.2%), bloating or abdominal pain in 22 patients (4.4%), nausea or vomiting in 26 patients (5.3%), and others (such as myalgia, headache, and bitter sensation in the mouth) in 10 patients (2.0%; Table 2).
Table 2 Adverse effects after bismuth-based quadruple therapy n (%).
1Others include myalgia, headache and bitter sensation in the mouth.
Associated factors for eradication failure
Associated factors for eradication failure are summarized in Table 3. Univariate and multivariate analyses demonstrated that only diabetes mellitus (OR = 3.99, 95%CI: 1.56-10.20, P = 0.004) was significantly related to eradication failure. There was no statistically significant relationship between eradication failure and other factors including age, gender, residence, smoking, alcohol, and hypertension.
Table 3 Related factors about eradication failure of bismuth-based quadruple therapy n (%).
1Total number of analyzed patients. Missing values are not included.
aP < 0.05, univariate logistic regression test;
cP < 0.05, multivariate logistic regression test. Logistic model including terms of age, gender, residence, cigarette smoking, alcohol intake, diabetes mellitus and hypertension.
In the current study, the H. pylori eradication rate for bismuth-containing quadruple therapy given for 7 d was < 80% by ITT analysis, but was > 90% by PP analysis in patients who failed clarithromycin-containing triple therapy. The frequency of adverse effects was less than 15%, which is consistent with the results of previous studies using bismuth-containing quadruple therapy[9,10].
As a second-line therapy, the effect of bismuth-containing quadruple therapy is controversial. Our PP eradication rate result was consistent with earlier studies, which reported that bismuth-containing quadruple therapy produced a high eradication rate in patients that failed H. pylori eradication therapy using clarithromycin-containing triple therapy. A recent multinational study in Europe reported the eradication rates for bismuth-containing quadruple therapy as rescue therapy for 10 d were 93.2%-93.8% by ITT analysis and 94.7%-95.0% by PP analysis. Results with bismuth-containing quadruple therapy in China also demonstrated a 10-d bismuth-containing quadruple therapy eradication rate of 88.9% by ITT analysis and 90.9%-91.6% by PP analysis in patients that failed H. pylori eradication therapy[12,13]. However, eradication rates using second-line bismuth-containing quadruple therapy revealed diverse results in South Korea. Yoon et al suggested that a 7-d bismuth-containing quadruple therapy might be as efficient as a 14-d bismuth-containing quadruple therapy for second-line eradication therapy, because a 7-d bismuth-containing quadruple therapy produced 83.5% and 87.7% eradication rates by ITT and PP analyses, respectively, and a 14-d bismuth-containing quadruple therapy produced 87.7% and 88.9% eradication rates by ITT and PP analyses, respectively. In contrast, another study reported that ITT eradication rates for a 7-d bismuth-containing quadruple therapy were 67.4%, and PP eradication rates were 78.2%, whereas ITT eradication rates for a 14-d bismuth-containing quadruple therapy were 72.8%, and PP eradication rates were 84.1%. Usually, H. pylori eradication rates correlate with patient drug compliance and H. pylori antibiotic resistance. Unfortunately, studies to evaluate antibiotic resistance between different areas in South Korea are rare, and one small study determined there was no significant regional difference between H. pylori metronidazole and tetracycline resistance in South Korea. Therefore, the reason for the high PP eradication rate in the current study is unclear. Although regional differences in antibiotic resistance may exist, bismuth-containing quadruple therapy achieved a more than 90% ITT eradication rate in patients who had H. pylori resistant to metronidazole (32.7%) and clarithromycin (63.3%). Thus, bismuth-containing quadruple therapy for second-line eradication therapy might even be effective in patients with antibiotic-resistant H. pylori.
In terms of adverse effects, most patients in the current study complained of gastrointestinal symptoms including nausea, vomiting, bloating, abdominal pain, or diarrhea. The symptoms were well tolerated, and no serious adverse events were observed. Only one patient wanted to be hospitalized for supportive care due to nausea. With regard to neurologic symptoms, three patients complained of headache or dizziness, but the symptoms were mild. Severe neurological symptoms, such as bismuth-related encephalopathy, were not observed[11,16,17]. In accordance with previous studies, bismuth-containing therapy for the eradication of H. pylori is considered safe and well tolerated[9,18].
Several factors have been postulated as the cause of eradication failure, including age, gender, smoking, alcohol, and specific drug history (e.g., aspirin)[6,19-22]. However, there was no significant relationship between these factors and eradication failure in the current study, except for diabetes mellitus. Diabetes mellitus has been presumed to be a risk factor for H. pylori eradication failure based on a recent meta-analysis (RR = 2.19, 95%CI: 1.65-2.90). It is hypothesized that microcirculatory complications related to diabetes mellitus could induce gastroparesis and reduce the absorption of antibiotics into the gastric mucosa, thereby influencing the effect of eradication therapy[24,25]. In addition, drug binding was revealed to be decreased by glycosylation, which was presumed to be associated with levels of blood glucose. Concerning antibiotic resistance, the frequent use of antibiotics might increase antibiotic resistance[23,27]. A recent Danish nationwide cohort study found that the rates for community-based antibiotic prescriptions were higher in patients with diabetes mellitus compared to the general population. Therefore, a more careful choice of H. pylori eradication therapy is needed for patients with diabetes mellitus.
Limitations of the present study are that it was performed at a single center and many patients were lost to follow-up, which might have influenced results of the ITT analysis. In addition, antibiotic susceptibility tests were not conducted in this study. Culturing H. pylori is difficult, and the response rates for antibiotic susceptibility tests are relatively low. Therefore, this was hard to inspect in all enrolled patients, and there were no standard criteria for identifying antibiotic resistance. Furthermore, we did not diagnose H. pylori by histology before and after eradication therapy, as most patients underwent the 13C-urea breath test or the rapid urease test for confirmation of H. pylori presence before and after therapy. These limitations could affect the eradication rate. According to the manufacturer, sensitivity and specificity of the rapid urease test were 90% to 95% and 95% to 100%, respectively. A recent meta-analysis reported that sensitivity and specificity of the 13C-urea breath test were 95% to 97% and 91% to 94%, respectively, and that this test only rarely provided false-positive results[29-32]. We found that eradication rates based on the 13C-urea breath test and the rapid urease test were 95.1% (327/344) and 93.4% (141/151), respectively (P = 0.519). Therefore, there was no significant difference between the two methods. The accuracy of both tests is high and very practical for clinical use, thus the absence of histology is unlikely to have had a significant effect on this study.
In conclusion, bismuth-containing quadruple therapy might be effective in patients that failed H. pylori eradication using clarithromycin-containing triple therapy, and might be worthy of consideration as a useful second-line therapy for H. pylori eradication in South Korea. Additionally, patients with diabetes mellitus are at higher risk for eradication failure with bismuth-containing quadruple therapy. Further studies on a larger scale evaluating the effects of second-line bismuth-containing quadruple therapy are needed in the near future in South Korea.
Helicobacter pylori (H. pylori) has been classified as a definite gastric carcinogen (group I) by the International Agency for Research on Cancer. Therefore, H. pylori eradication is important to protect public health, especially in areas with high H. pylori prevalence. However, the eradication rate for proton pump inhibitor (PPI)-containing triple therapy has decreased worldwide, and an effective rescue treatment is needed.
There is controversy about the role of bismuth-containing quadruple therapy as a second-line therapy for H. pylori eradication due to a decrease in eradication rates for bismuth-containing quadruple therapy in South Korea. In addition, risk factors related to the failure of second-line eradication therapy are obscure.
Innovations and breakthroughs
This retrospective study was performed to investigate the effects of second-line eradication therapy using bismuth-containing quadruple therapy at a single center over the past 11 years, and to evaluate the risk factors associated with the failure of second-line eradication therapy. According to the high eradication rate and low adverse effects of the therapy, bismuth-containing quadruple therapy is worthy of consideration as a useful second-line therapy for H. pylori eradication in South Korea. Additionally, diabetes mellitus is suggested to be a risk factor for eradication failure.
This retrospective study’s design and findings may be helpful for planning further prospective studies on a larger scale which can evaluate the effects of second-line bismuth-containing quadruple therapy and clarify additional risk factors for eradication failure.
H. pylori: A global pathogen that causes gastritis, peptic ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Eradication of H. pylori infection is crucial to maintaining public health, especially in high H. pylori and gastric cancer prevalence areas.
This is a well-designed, although retrospective study including a high number of patients. The methods used are appropriate, the statistics is sound. The difference between intention-to-treat and per-protocol eradication rates reflects the real life, while a proportion of patients lost to follow up is high.
Manuscript source: Unsolicited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: South Korea
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C, C
Grade D (Fair): 0
Grade E (Poor): 0
P- Reviewer: Buzas GM, Karatapanis S, Slomiany BL, Suzuki H S- Editor: Gong ZM L- Editor: A E- Editor: Liu WX
IARC working group. IARC working group on the evaluation of carcinogenic risks to humans: some industrial chemicals. Lyon, 15-22 February 1994.IARC Monogr Eval Carcinog Risks Hum. 1994;60:1-560.
[PubMed] [DOI][Cited in This Article: ]
Zheng Q, Dai J, Li X, Lu H, Xiao S. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infections: a single-center, randomized, open and parallel-controlled study.Weichangbingxue. 2009;14:8-11.
[PubMed] [DOI][Cited in This Article: ]
Serfontein WJ, Mekel R. Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man.Res Commun Chem Pathol Pharmacol. 1979;26:391-411.
[PubMed] [DOI][Cited in This Article: ]
Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R. Smoking increases the treatment failure for Helicobacter pylori eradication.Am J Med. 2006;119:217-224.
[PubMed] [DOI][Cited in This Article: ]
Cho DK, Park SY, Kee WJ, Lee JH, Ki HS, Yoon KW, Cho SB, Lee WS, Joo YE, Kim HS. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy.Korean J Gastroenterol. 2010;55:368-375.
[PubMed] [DOI][Cited in This Article: ]
Mor A, Berencsi K, Nielsen JS, Rungby J, Friborg S, Brandslund I, Christiansen JS, Vaag A, Beck-Nielsen H, Sørensen HT. Rates of Community-based Antibiotic Prescriptions and Hospital-treated Infections in Individuals With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study, 2004-2012.Clin Infect Dis. 2016;63:501-511.
[PubMed] [DOI][Cited in This Article: ]